WO2008050698A2 - Agent for prophylaxis or treatment of alcohol dependence or drug dependence - Google Patents
Agent for prophylaxis or treatment of alcohol dependence or drug dependence Download PDFInfo
- Publication number
- WO2008050698A2 WO2008050698A2 PCT/JP2007/070502 JP2007070502W WO2008050698A2 WO 2008050698 A2 WO2008050698 A2 WO 2008050698A2 JP 2007070502 W JP2007070502 W JP 2007070502W WO 2008050698 A2 WO2008050698 A2 WO 2008050698A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lower alkyl
- dihydro
- acenaphthen
- piperidin
- benzimidazol
- Prior art date
Links
- 208000011117 substance-related disease Diseases 0.000 title claims abstract description 47
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 title claims description 19
- 208000007848 Alcoholism Diseases 0.000 title description 9
- 201000007930 alcohol dependence Diseases 0.000 title description 7
- 206010013663 drug dependence Diseases 0.000 title description 3
- 201000009032 substance abuse Diseases 0.000 claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 231100000736 substance abuse Toxicity 0.000 claims abstract description 24
- 201000006152 substance dependence Diseases 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- PJANMOWVUZBDQF-XMMPIXPASA-N 2-[3-[1-[(1r)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]-n-methylacetamide Chemical compound C1=CC([C@H](N2CCC(CC2)N2C3=CC=CC=C3N(C2=O)CC(=O)NC)C2)=C3C2=CC=CC3=C1 PJANMOWVUZBDQF-XMMPIXPASA-N 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 77
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 30
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 28
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 25
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 125000004094 acenaphthen-1-yl group Chemical group [H]C1=C([H])C2=C3C(=C([H])C([H])=C([H])C3=C1[H])C([H])([H])C2([H])* 0.000 claims description 21
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 18
- -1 phenoxy, benzyloxy Chemical group 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 229940049706 benzodiazepine Drugs 0.000 claims description 9
- 150000001557 benzodiazepines Chemical class 0.000 claims description 9
- 229960003920 cocaine Drugs 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 8
- 229960001252 methamphetamine Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 7
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 7
- 229940125717 barbiturate Drugs 0.000 claims description 7
- 239000000380 hallucinogen Substances 0.000 claims description 7
- 229960003299 ketamine Drugs 0.000 claims description 7
- 229960002715 nicotine Drugs 0.000 claims description 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 7
- 229940005483 opioid analgesics Drugs 0.000 claims description 7
- 229950010883 phencyclidine Drugs 0.000 claims description 7
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 7
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 6
- 229940025084 amphetamine Drugs 0.000 claims description 6
- QRJFBWUTXOQCPI-XMMPIXPASA-N 1-acetyl-3-[1-[(1r)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]benzimidazol-2-one Chemical compound C1=CC([C@H](N2CCC(CC2)N2C3=CC=CC=C3N(C2=O)C(=O)C)C2)=C3C2=CC=CC3=C1 QRJFBWUTXOQCPI-XMMPIXPASA-N 0.000 claims description 5
- NQLVHFRVXIMNPX-UHFFFAOYSA-N 3-[1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-yl]-6-fluoro-1h-benzimidazol-2-one Chemical compound C1=CC(C(N2CCC(CC2)N2C3=CC=C(C=C3NC2=O)F)C2)=C3C2=CC=CC3=C1 NQLVHFRVXIMNPX-UHFFFAOYSA-N 0.000 claims description 5
- VSKOUBDVXYXQKC-QFIPXVFZSA-N 3-[1-[(1s)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC([C@@H](N2CCC(CC2)N2C3=CC=CC=C3NC2=O)C2)=C3C2=CC=CC3=C1 VSKOUBDVXYXQKC-QFIPXVFZSA-N 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- YOKHRKNKLYVHHH-UHFFFAOYSA-N 1-[1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-yl]-3-(2-morpholin-4-yl-2-oxoethyl)benzimidazol-2-one;hydrochloride Chemical compound Cl.C12=CC=CC=C2N(C2CCN(CC2)C2C=3C=CC=C4C=CC=C(C=34)C2)C(=O)N1CC(=O)N1CCOCC1 YOKHRKNKLYVHHH-UHFFFAOYSA-N 0.000 claims description 4
- UWGJOUYXZVSPHU-UHFFFAOYSA-N 1-[1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-yl]-3-(2-oxo-2-piperazin-1-ylethyl)benzimidazol-2-one;dihydrochloride Chemical compound Cl.Cl.C12=CC=CC=C2N(C2CCN(CC2)C2C=3C=CC=C4C=CC=C(C=34)C2)C(=O)N1CC(=O)N1CCNCC1 UWGJOUYXZVSPHU-UHFFFAOYSA-N 0.000 claims description 4
- QDYOLOJRYOAQMD-UHFFFAOYSA-N 1-[1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-yl]-3-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]benzimidazol-2-one;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1C(=O)CN1C(=O)N(C2CCN(CC2)C2C=3C=CC=C4C=CC=C(C=34)C2)C2=CC=CC=C21 QDYOLOJRYOAQMD-UHFFFAOYSA-N 0.000 claims description 4
- VSKOUBDVXYXQKC-JOCHJYFZSA-N 3-[1-[(1r)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC([C@H](N2CCC(CC2)N2C3=CC=CC=C3NC2=O)C2)=C3C2=CC=CC3=C1 VSKOUBDVXYXQKC-JOCHJYFZSA-N 0.000 claims description 4
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- FZDZRNFONSFREU-UHFFFAOYSA-N 1-[1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-yl]-3-methylbenzimidazole-2-thione Chemical compound C1=CC(C(N2CCC(CC2)N2C3=CC=CC=C3N(C2=S)C)C2)=C3C2=CC=CC3=C1 FZDZRNFONSFREU-UHFFFAOYSA-N 0.000 claims description 3
- VSKOUBDVXYXQKC-UHFFFAOYSA-N 3-[1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC(C(N2CCC(CC2)N2C3=CC=CC=C3NC2=O)C2)=C3C2=CC=CC3=C1 VSKOUBDVXYXQKC-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- OXVWFQNPVAVRJP-UHFFFAOYSA-N ethyl 2-[3-[1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-yl]-2-oxobenzimidazol-1-yl]acetate Chemical compound C1=CC(C(N2CCC(CC2)N2C3=CC=CC=C3N(C2=O)CC(=O)OCC)C2)=C3C2=CC=CC3=C1 OXVWFQNPVAVRJP-UHFFFAOYSA-N 0.000 claims description 2
- OXVWFQNPVAVRJP-RUZDIDTESA-N ethyl 2-[3-[1-[(1r)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]acetate Chemical compound C1=CC([C@H](N2CCC(CC2)N2C3=CC=CC=C3N(C2=O)CC(=O)OCC)C2)=C3C2=CC=CC3=C1 OXVWFQNPVAVRJP-RUZDIDTESA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 2
- UWGJOUYXZVSPHU-KFSCGDPASA-N 1-[1-[(1r)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]-3-(2-oxo-2-piperazin-1-ylethyl)benzimidazol-2-one;dihydrochloride Chemical compound Cl.Cl.C12=CC=CC=C2N(C2CCN(CC2)[C@H]2C=3C=CC=C4C=CC=C(C=34)C2)C(=O)N1CC(=O)N1CCNCC1 UWGJOUYXZVSPHU-KFSCGDPASA-N 0.000 claims 3
- YMIIIZCXNDXWKI-UHFFFAOYSA-N 3-[1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-yl]-1h-benzimidazole-2-thione Chemical compound C1=CC(C(N2CCC(CC2)N2C3=CC=CC=C3NC2=S)C2)=C3C2=CC=CC3=C1 YMIIIZCXNDXWKI-UHFFFAOYSA-N 0.000 claims 3
- 241000218236 Cannabis Species 0.000 claims 3
- INTNSBFJAWHSBA-UHFFFAOYSA-N 2-[3-[1-(1,2-dihydroacenaphthylen-1-yl)piperidin-4-yl]-2-oxobenzimidazol-1-yl]acetic acid Chemical compound C1=CC(C(N2CCC(CC2)N2C3=CC=CC=C3N(C2=O)CC(=O)O)C2)=C3C2=CC=CC3=C1 INTNSBFJAWHSBA-UHFFFAOYSA-N 0.000 claims 2
- PAMHCZPPOIUIAS-RUZDIDTESA-N 2-[3-[1-[(1r)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]-n,n-dimethylacetamide Chemical compound C1=CC([C@H](N2CCC(CC2)N2C3=CC=CC=C3N(C2=O)CC(=O)N(C)C)C2)=C3C2=CC=CC3=C1 PAMHCZPPOIUIAS-RUZDIDTESA-N 0.000 claims 2
- INTNSBFJAWHSBA-HSZRJFAPSA-N 2-[3-[1-[(1r)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]acetic acid Chemical compound C1=CC([C@H](N2CCC(CC2)N2C3=CC=CC=C3N(C2=O)CC(=O)O)C2)=C3C2=CC=CC3=C1 INTNSBFJAWHSBA-HSZRJFAPSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- LWXBXCXQJREPPE-HSZRJFAPSA-N 1-[1-[(1r)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]-3-methylsulfonylbenzimidazol-2-one Chemical compound C1=CC([C@H](N2CCC(CC2)N2C3=CC=CC=C3N(C2=O)S(=O)(=O)C)C2)=C3C2=CC=CC3=C1 LWXBXCXQJREPPE-HSZRJFAPSA-N 0.000 claims 1
- PGVGNKRBHNUZBT-HSZRJFAPSA-N 2-[3-[1-[(1r)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]acetamide Chemical compound C1=CC([C@H](N2CCC(CC2)N2C3=CC=CC=C3N(C2=O)CC(=O)N)C2)=C3C2=CC=CC3=C1 PGVGNKRBHNUZBT-HSZRJFAPSA-N 0.000 claims 1
- JKNGDFLICFBWJW-UHFFFAOYSA-N 4-methylbenzimidazole-2-thione Chemical compound CC1=CC=CC2=NC(=S)N=C12 JKNGDFLICFBWJW-UHFFFAOYSA-N 0.000 claims 1
- OMNJSRSOALSTOR-UHFFFAOYSA-N C1(CC2=CC=CC3=CC=CC1=C23)N2CCC(CC2)N2CNC3=C2C=CC=C3 Chemical compound C1(CC2=CC=CC3=CC=CC1=C23)N2CCC(CC2)N2CNC3=C2C=CC=C3 OMNJSRSOALSTOR-UHFFFAOYSA-N 0.000 claims 1
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 24
- 229940126062 Compound A Drugs 0.000 description 20
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 20
- 108010020615 nociceptin receptor Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 208000029650 alcohol withdrawal Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 6
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 239000008177 pharmaceutical agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 6
- 229960000317 yohimbine Drugs 0.000 description 6
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 6
- 230000008033 biological extinction Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 4
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 4
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 4
- 102400001111 Nociceptin Human genes 0.000 description 4
- 108090000622 Nociceptin Proteins 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 240000004308 marijuana Species 0.000 description 4
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 4
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 239000004866 Hashish Substances 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 2
- 229960003386 triazolam Drugs 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- HCUOEKSZWPGJIM-YBRHCDHNSA-N (e,2e)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N/O)\C(N)=O HCUOEKSZWPGJIM-YBRHCDHNSA-N 0.000 description 1
- QNISUXXGSWDXSQ-HHHXNRCGSA-N 1-[1-[(1r)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]-3-(2-oxo-2-piperazin-1-ylethyl)benzimidazol-2-one Chemical compound C12=CC=CC=C2N(C2CCN(CC2)[C@H]2C=3C=CC=C4C=CC=C(C=34)C2)C(=O)N1CC(=O)N1CCNCC1 QNISUXXGSWDXSQ-HHHXNRCGSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000003698 Heroin Dependence Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- 101500026205 Rattus norvegicus Nociceptin Proteins 0.000 description 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
- 229960004047 acamprosate Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000001814 effect on stress Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000008013 morphine dependence Diseases 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Definitions
- the present invention relates to an agent for the prophylaxis or treatment of substance abuse and dependence, which comprises an ORL-I receptor agonist as an active ingredient .
- ORL-I opioid receptor-like 1
- ORL-I receptor has about 60% of homology to other opioid receptors, it is clearly different from other opioid receptors, because non-selective opioid receptor antagonist, naloxone, does not bind to the ORL-I receptor (FEBS Lett. 341, 33-38, 1994) .
- ORL-I receptor While the ORL-I receptor is expressed in the periphery organs such as intestine, spleen and so on, it is also widely expressed in the central nervous system, especially in the cortex, hippocampus, hypothalamus, amygdala and spinal cord (Eur. J. Pharmacol. 340, 1-15, 1997, Pharmacol. Rev. 53, 381-415, 2001) .
- the endogenous ligand for the ORL-I receptor was identified by two different research groups in France and Switzerland at the same time, and named as nociceptin (Nature 377, 532-535, 1995) and orphanin FQ (Science 270, 792-794, 1995) , respectively.
- Nociceptin is a 17-amino acid peptide and plays an important role in the function of central nervous system such as learning, memory, anxiety and stress (Br. J. Pharmacol. 129, 1261-1283, 2000).
- Substance abuse and dependence involves any of following classes of substances: alcohol, amphetamine, methamphetamine, cannabis (including marijuana, hashish) , cocaine, hallucinogens (including LSD, mescaline, MDMA) , nicotine, opioids (including morphine, heroin, codeine, methadone) , phencyclidine, ketamine, barbiturates, benzodiazepines (including diazepam, triazolam) , inhalants (including toluene, paint thinner). It is known that the nociceptin, an endogenous agonist for the ORL-I receptor, is effective in alcohol dependence (Ciccocioppo et al., Psychopharmacology (Berl) .
- buprenorphine a partial agonist at ⁇ opioid and ORL-I receptors
- Buprenorphine also reduces cocaine use by dually opiate- dependent and cocaine-dependent outpatients (Montoya et al., Clin Pharmacol Ther 75, 34-48, 2004; Schottenfeld et al., Biol Psychiatry 34, 66-74, 1993) .
- ORL-I receptor agonist is expected to be effective in the prophylaxis or treatment of for substance abuse and dependence.
- first synthesized ORL- 1 receptor agonist Ro64-6198 failed to decrease alcohol drinking, rather increase it at high dose (Economidou et al., Peptides 27, 3299-3306, 2006). This effect probably induced by its residual agonistic activity at ⁇ opioid receptors.
- the present inventors have evaluated the effectiveness of the ORL-I receptor agonist, (R) -2- ⁇ 3- [1- (acenaphten-1- yl) piperidin-4-yl] -2, 3-dihydro-2-oxo-benzimidazol-l-yl ⁇ -N- methylacetamide, in alcohol dependence rat model and found that this compound significantly inhibits alcohol intake of the rat model. Further studies have resulted in the completion of the present invention.
- an agent for the prophylaxis or treatment of substance abuse and dependence which comprises a compound represented by the formula (I)
- R 1 is (1) hydrogen
- phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , or
- benzyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy)
- R 2 is hydrogen, lower alkyl, halogen, lower alkoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, amino or cyano
- R 3 and R 4 may be the same or different, and each is hydrogen, lower alkyl or lower alkenyl, or R 3 and R 4 may bind with an adjacent nitrogen atom to form a saturated nitrogen- containing hetero ring (the hetero ring may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , and X is 0 or S. ), or a pharmaceutically acceptable salt thereof as an active ingredient.
- R 1 , R 2 and X are the same as defined above, 5 or a pharmaceutically acceptable salt thereof for the production of an agent for the prophylaxis or treatment of substance abuse and dependence.
- a method for the prophylaxis or treatment of substance0 abuse and dependence which comprises administering an effective amount of compound represented by the formula (I) wherein R 1 , R 2 and X are the same as defined above, or a pharmaceutically acceptable salt thereof.
- lower alkyl means alkyl having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl or hexyl
- lower alkenyl means alkenyl having 2 to 6 carbon atoms such as vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl or 3-butenyl
- lower alkoxy means alkoxy having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy or hexyloxy
- halogen means chlorine, fluorine, iodine or bromine.
- Fig. 1 shows a test protocol of alcohol withdrawal.
- Fig. 2 shows the action of Compound A on alcohol withdrawal symptoms.
- Fig. 3 shows a test protocol of ethanol intake measurement in msP rats .
- Fig. 4 shows the action of Compound A on the ethanol intake in msP rats.
- Fig. 5 shows a test protocol of yohimbine-induced reinstatement in msP rats.
- Fig. 6 shows the action of Compound A on yohimbine- induced reinstatement in msP rats.
- Fig. 7 shows a test protocol of the conditioned place preference in msP rats.
- Fig. 8 shows the effect of Compound A on the place preference in msP rats. Effect of the Invention
- the present invention provides an agent effective in the prophylaxis or treatment of substance abuse and dependence. More particularly, the present invention provides a pharmaceutical agent useful for the prophylaxis or treatment of excessive alcohol intake, alcohol dependence and the like, as well as a pharmaceutical agent useful for the prophylaxis or treatment of other substance abuse of and dependence on amphetamine, methamphetamine, cannabis, cocaine, hallucinogens, nicotine, opioids, phencyclidine, ketamine, barbiturates, benzodiazepines, inhalants and the like.
- the "substance abuse and dependence” includes abuse of and dependence on alcohol, amphetamine, methamphetamine, cannabis (including marijuana, hashish) , cocaine, hallucinogens (including LSD, mescaline, MDMA) , nicotine, opioids (including morphine, heroin, codeine, methadone) , phencyclidine, ketamine, barbiturates, benzodiazepines (including diazepam, triazolam) , inhalants (including toluene, paint thinner) and the like.
- the agent for the prophylaxis or treatment of substance abuse and dependence of the present invention contains a compound represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- R 1 is -C(O) -lower alkyl, lower alkyl-C (O)NR 3 R 4 (either R 3 or R 4 is hydrogen and the other is lower alkyl) or lower alkyl-C (O)NR 3 R 4 wherein R 3 and R 4 bind with an adjacent nitrogen atom to form a saturated nitrogen-containing hetero ring (the hetero ring may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) .
- R 2 is hydrogen
- preferable X is 0.
- (R) -2- ⁇ 3- [1- (acenaphthen- 1-yl) piperidin-4-yl] -2, 3-dihydro-2-oxo-benzimidazol-l-yl ⁇ -N- methylacetamide is the most preferable compound.
- the compound represented by the formula (I) can be synthesized according to the methods described in WO03/082333.
- Compound A As the pharmaceutically acceptable salt, acid addition salts with inorganic acid and organic acid can be mentioned.
- the pharmaceutical agent of the present invention can be administered orally or non-orally.
- Dosage form includes tablet, capsule, granule, powder, injection, oral tablet, lotion, liniment, ointment, suppository and the like. These can be formulated by generally used techniques .
- the amount of compound (I) or a pharmaceutically acceptable salt thereof, an active ingredient in these formulations is 0.1 to 100% by weight, suitably 1 to 50% by weight.
- the dose may be suitably determined depending on symptoms, age, dosage form and the like.
- the dose is usually 0.1 to 5000 mg, preferably 1 to 1000 mg per day, and may be administered in a single dose or divided doses.
- mice Male Wistar rats were used in this study. According to the protocol shown in Figure 1, rats were orally given 12-15 g/kg/body weight of ethanol in 24 hours on day 1 to day 2 and 9-10 g/kg/body weight of ethanol in 12 hours on day 3 to day 5. Compound A was administered p.o. at doses of 0.3 and 1 mg/kg/body weight twice after 2 and 7 hours of last ethanol administration.
- Compound A significantly and dose-dependently decreased ethanol consumption in msP rats. This effect was long-lasting and significant for 9 days after withdrawal of Compound A.
- rats were trained to self- administer 10% (w/v) ethanol in 30-min daily sessions under a fixed-ratio 1 (FR 1) schedule of reinforcement, where each response resulted in delivery of 0.1 ml fluid. After acquisition of a stable baseline of 10% ethanol self-
- rats were subjected to 30-min extinction sessions for 15 consecutive days. Extinction sessions were identical to 10% ethanol self-administration sessions, however alcohol was no longer available. Beginning on extinction day 10, rats were divided into three groups with similar baseline levels of responding for 10% ethanol. For six consecutive days, 1 hour before the self-administration session and 8 hours later, each group of rats were orally given vehicle, 0.3 mg/kg of Compound A or 1.0 mg/kg of Compound A. After the extinction sessions, rats were given yohimbine (1,25 mg/kg, i.p.) 35 min before the test sessions. The 30-min reinstatement test was conducted under extinction condition.
- Yohimbine was used as stressor for this study, because yohimbine is known to produce stress and anxiety-like states in both humans and non-humans (Bremner et al, 1996; Charney et al 1983; Holmberg et al 1963) . (Results)
- a two-compartment box divided by guillotine door was used. As shown in Figure 7, in the first two days, rats were allowed to explore the box with guillotine door open for 15 min (pre-conditioning) . For the following 6 days, the rats were treated on alternate days with three Compound A-pairing administrations (0.3 and 1.0 mg/kg/body weight, p.o.) and three vehicle-pairing administrations immediately before being placed, for 1 hour, into the assigned chamber with guillotine door close for drug-compartment discrimination (conditioning) . The day after the last conditioning session, the rats were placed, for 15 min, in the box with door open. The time spent in the drug paired compartment was measured. (Results)
- Alpha-2 adrenergic agonists represented by clonidine are also effective in alcohol withdrawal symptoms (Dobrydnjov et al., Anesth Analg. 98, 738-744, 2004), but ineffective in excessive alcohol intake and stress-induced reinstatement.
- Compound A has not only suppressive effect on excessive alcohol intake, but also ameliorative effect on alcohol withdrawal symptoms and suppressive effect on stress-induced reinstatement. Furthermore, Compound A itself does not elicit dependence. From these results, Compound A is expected to be a good agent for the prophylaxis ⁇ or treatment of alcohol abuse and dependence and other substance abuse and dependence.
- Example 1 formulation example (tablet)
- the pharmaceutical agent of the present invention can be is used as an agent for the prophylaxis or treatment of substance abuse and dependence.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Addiction (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides an agent for the prophylaxis or treatment of substance abuse and dependence, which contains a compound of the formula (I) represented by (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, or a pharmaceutically acceptable salt thereof as an active ingredient.
Description
DESCRIPTION
AGENT FOR PROPHYLAXIS OR TREATMENT OF SUBSTANCE ABUSE AND
DEPENDENCE
Technical Field
The present invention relates to an agent for the prophylaxis or treatment of substance abuse and dependence, which comprises an ORL-I receptor agonist as an active ingredient .
Background Art
After cloning of δ, K, μ receptors, the opioid receptor- like 1 (ORL-I) receptor was cloned as the forth member of the opioid receptor family in 1994, (FEBS Lett. 347, 284-288, 1994, FEBS Lett. 341, 33-38, 1994) . Although ORL-I receptor has about 60% of homology to other opioid receptors, it is clearly different from other opioid receptors, because non-selective opioid receptor antagonist, naloxone, does not bind to the ORL-I receptor (FEBS Lett. 341, 33-38, 1994) . While the ORL-I receptor is expressed in the periphery organs such as intestine, spleen and so on, it is also widely expressed in the central nervous system, especially in the cortex, hippocampus, hypothalamus, amygdala and spinal cord (Eur. J. Pharmacol. 340, 1-15, 1997, Pharmacol. Rev. 53, 381-415, 2001) . In 1995, the endogenous ligand for the ORL-I receptor was identified by two different research groups in France and Switzerland at the same time, and named as nociceptin (Nature 377, 532-535, 1995) and orphanin FQ (Science 270, 792-794, 1995) , respectively. Nociceptin is a 17-amino acid peptide and plays an important role in the function of central nervous system such as learning, memory, anxiety and stress (Br. J. Pharmacol. 129, 1261-1283, 2000).
Substance abuse and dependence involves any of following classes of substances: alcohol, amphetamine, methamphetamine, cannabis (including marijuana, hashish) , cocaine, hallucinogens
(including LSD, mescaline, MDMA) , nicotine, opioids (including morphine, heroin, codeine, methadone) , phencyclidine, ketamine, barbiturates, benzodiazepines (including diazepam, triazolam) , inhalants (including toluene, paint thinner). It is known that the nociceptin, an endogenous agonist for the ORL-I receptor, is effective in alcohol dependence (Ciccocioppo et al., Psychopharmacology (Berl) . 141, 220-224, 1999; Ciccocioppo et al . , Psychopharmacology (Berl) 172, 170- 178, 2004; Martin-Fardon et al., NeuroReport. 11, 1939-1943, 2000), morphine or cocaine dependence (Sakoori et al.,
Psychopharmacology (Berl) 172, 129-136, 2004), methamphetamine dependence (Zhao et al., NeuroReport. 14, 2383-2385, 2003).
Furthermore, buprenorphine, a partial agonist at μ opioid and ORL-I receptors, has been used in clinical for treatment of heroin dependence in numerous countries including the United States, Australia, Sweden and France (Kakko et al., Lancet 361, 662-668, 2003; Ling et al., Addiction 93, 475-486, 1998). Buprenorphine also reduces cocaine use by dually opiate- dependent and cocaine-dependent outpatients (Montoya et al., Clin Pharmacol Ther 75, 34-48, 2004; Schottenfeld et al., Biol Psychiatry 34, 66-74, 1993) . More recently, evidence has accumulated in support of its efficacy for treatment of alcohol abuse and dependence (Ciccocioppo et al., Biol Psychiatry 61, 4-12, 2007). Therefore a small molecule ORL-I receptor agonist is expected to be effective in the prophylaxis or treatment of for substance abuse and dependence. However, first synthesized ORL- 1 receptor agonist Ro64-6198 failed to decrease alcohol drinking, rather increase it at high dose (Economidou et al., Peptides 27, 3299-3306, 2006). This effect probably induced by its residual agonistic activity at μ opioid receptors.
The compound of represented by the formula (I) mentioned in the below, for example, (R) -2- {3- [1- (acenaphthen-1- yl)piperidin-4-yl] -2, 3-dihydro-2-oxo-benzimidazol-l-yl}-N- methylacetamide (same as 2-{3- [1- ( (IR) -acenaphthen-1-
yl) piperidin-4-yl] -2, 3-dihydro-2-oxo-benzimidazol-l-yl } -N- methylacetamide) , is another agonist which possesses highly selective affinity for ORL-I receptors (WO03/082333) .
Disclosure of the Invention
The present inventors have evaluated the effectiveness of the ORL-I receptor agonist, (R) -2-{3- [1- (acenaphten-1- yl) piperidin-4-yl] -2, 3-dihydro-2-oxo-benzimidazol-l-yl}-N- methylacetamide, in alcohol dependence rat model and found that this compound significantly inhibits alcohol intake of the rat model. Further studies have resulted in the completion of the present invention.
Accordingly, the present invention provides the following. 1. An agent for the prophylaxis or treatment of substance abuse and dependence, which comprises a compound represented by the formula (I)
(2) lower alkyl,
(3) lower alkenyl,
(4) -C(O) -lower alkyl,
(5) -C(0)0-lower alkyl, (6) -C(O) -phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) ,
(7) lower alkyl-carboxyl,
(8) lower alkyl-C (0) -phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) ,
(9) lower alkyl-C (0) 0-lower alkyl,
(10) lower alkenyl-C (O) 0-lower alkyl,
(11) lower alkyl-0-lower alkyl,
(12) lower alkyl-C (O)NR3R4,
(13) -S(0)2-lower alkyl, (14) -S (O)2-phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) ,
(15) lower alkyl-S-lower alkyl,
(16) lower alkyl-S (0) -lower alkyl,
(17) lower alkyl-S (0) 2-lower alkyl, (18) lower alkyl-S (0) 2NR3R4,
(19) phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , or
(20) benzyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , R2 is hydrogen, lower alkyl, halogen, lower alkoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, amino or cyano, R3 and R4 may be the same or different, and each is hydrogen, lower alkyl or lower alkenyl, or R3 and R4 may bind with an adjacent nitrogen atom to form a saturated nitrogen- containing hetero ring (the hetero ring may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , and X is 0 or S. ), or a pharmaceutically acceptable salt thereof as an active ingredient.
2. The agent of above-mentioned 1, wherein the substance abuse and dependence is abuse of and dependence on alcohol, amphetamine, methamphetamine, cannabis, cocaine, hallucinogens, nicotine, opioids, phencyclidine, ketamine, barbiturates, benzodiazepines or inhalants.
3. The agent of above-mentioned 1, wherein the substance abuse and dependence is abuse of and dependence on alcohol.
4. The agent of above-mentioned 1, wherein the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof is a compound selected from [1] (RS) -1- [1- (acenaphthen-1-yl)piperidin-4-yl] -1, 3-dihydro- 2H-benzimidazol-2-one,
[2] (RS) -1- [1- (acenaphthen-l-yl)piperidin-4-yl] -1, 3-dihydro-5- fluoro-2H-benzimidazol-2-one,
[3] (RS)-I-[I- (acenaphthen-1-yl) piperidin-4-yl] -l,3-dihydro~6- fluoro-2H-benzimidazol-2-one,
[4] ethyl (RS) -2-{3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2, 3- dihydro-2-oxo-benzimidazol-l-yl}acetate, [5] (RS) -2-{3- [1- (acenaρhthen-1-yl) piperidin-4-yl] -2, 3- dihydro-2-oxo-benzimidazol-l-yl}acetic acid, [6] (RS) -1-[1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2-oxo-2- piperazin-1-ylethyl) -1, 3-dihydro-2H-benzimidazol-2-one dihydrochloride,
[7] (RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- [2- (4- methylpiperazin-1-yl) -2-oxoethyl] -1, 3-dihydro-2H-benzimidazol- 2-one dihydrochloride,
[8] (RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2- morpholin-4-yl-2-oxoethyl) -1, 3-dihydro-2H-benzimidazol-2-one hydrochloride,
[9] (RS) -1-[1- (acenaphthen-1-yl) pip'eridin-4-yl] -1, 3-dihydro- 2H-benzimidazole-2-thione,
[10] (RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro- 3-methyl-2H-benzimidazole-2-thione,
[11] (R) -1-[1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro- 2H-benzimidazol-2-one, [12] (S) -1-[1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro- 2H-benzimidazol-2-one,
[13] (R) -3-acetyl-l- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3- dihydro-2H-benzimidazol-2-one,
[14] (R)-I-[I- (acenaphthen-1-yl) piperidin-4-yl] -3- methanesulfonyl-1, 3-dihydro-2H-benzimidazol-2-one,
[15] ethyl (R) -2-{3- [1- (acenaphthen-l-yl)piperidin-4-yl] -2, 3- dihydro-2-oxo-benzimidazol-l-yl}acetate, [16] (R)-2-{3-[l-(acenaphthen-l-yl)piρeridin-4-yl]-2,3- dihydro-2-oxo-benzimidazol-l-yl } acetic acid, s [17] (R)-l-[l-(acenaphthen-l-yl)piperidin-4-yl]-3-(2-oxo-2- piperazin-1-ylethyl) -1, 3-dihydro-2H-benzimidazol-2-one dihydrochloride,
[18] (R)-2-{3-[l-(acenaphthen-l-yl)piperidin-4-yl]-2, 3- dihydro-2-oxo-benzimidazol-l-yl}-N-methylacetamide, o [19] (R)-2-{3-[l- (acenaphthen-l-yl)piperidin-4-yl]-2,3- dihydro-2-oxo-benzimidazol-l-yl } -N, N-dimethylacetamide, and [20] (R) -2-{3-[l-(acenaphthen-l-yl)piperidin-4-yl]-2,3- dihydro-2-oxo-benzimidazol-l-yl } acetamide . 5 5. The agent of above-mentioned 1, wherein the compound represented by the formula (I) is (R) -2~{3- [1- (acenaphthen-1- yl)piperidin-4-yl] -2, 3-dihydro-2-oxo-benzimidazol-l-yl}-N- methylacetamide . 0 The present invention further provides the following. 6. Use of a compound represented by the formula (I)
7. A method for the prophylaxis or treatment of substance0 abuse and dependence, which comprises administering an effective amount of compound represented by the formula (I)
wherein R1, R2 and X are the same as defined above, or a pharmaceutically acceptable salt thereof.
In the present specification, lower alkyl means alkyl having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl or hexyl, lower alkenyl means alkenyl having 2 to 6 carbon atoms such as vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl or 3-butenyl, lower alkoxy means alkoxy having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy or hexyloxy, and halogen means chlorine, fluorine, iodine or bromine.
Brief Description of the Drawings
Fig. 1 shows a test protocol of alcohol withdrawal.
Fig. 2 shows the action of Compound A on alcohol withdrawal symptoms. Fig. 3 shows a test protocol of ethanol intake measurement in msP rats .
Fig. 4 shows the action of Compound A on the ethanol intake in msP rats.
Fig. 5 shows a test protocol of yohimbine-induced reinstatement in msP rats.
Fig. 6 shows the action of Compound A on yohimbine- induced reinstatement in msP rats.
Fig. 7 shows a test protocol of the conditioned place preference in msP rats. Fig. 8 shows the effect of Compound A on the place preference in msP rats.
Effect of the Invention
The present invention provides an agent effective in the prophylaxis or treatment of substance abuse and dependence. More particularly, the present invention provides a pharmaceutical agent useful for the prophylaxis or treatment of excessive alcohol intake, alcohol dependence and the like, as well as a pharmaceutical agent useful for the prophylaxis or treatment of other substance abuse of and dependence on amphetamine, methamphetamine, cannabis, cocaine, hallucinogens, nicotine, opioids, phencyclidine, ketamine, barbiturates, benzodiazepines, inhalants and the like.
Best Mode for Embodying the Invention The present invention is explained in detail in the following.
In the present invention, the "substance abuse and dependence" includes abuse of and dependence on alcohol, amphetamine, methamphetamine, cannabis (including marijuana, hashish) , cocaine, hallucinogens (including LSD, mescaline, MDMA) , nicotine, opioids (including morphine, heroin, codeine, methadone) , phencyclidine, ketamine, barbiturates, benzodiazepines (including diazepam, triazolam) , inhalants (including toluene, paint thinner) and the like. The agent for the prophylaxis or treatment of substance abuse and dependence of the present invention (hereinafter sometimes to be referred to as the pharmaceutical agent of the present invention) contains a compound represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
In the compound represented by the formula (I) , preferable R1 is -C(O) -lower alkyl, lower alkyl-C (O)NR3R4 (either R3 or R4 is hydrogen and the other is lower alkyl) or lower alkyl-C (O)NR3R4 wherein R3 and R4 bind with an adjacent
nitrogen atom to form a saturated nitrogen-containing hetero ring (the hetero ring may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) . Preferable R2 is hydrogen, and preferable X is 0.
The following compounds included in the formula (I) are more preferable in the present invention.
(RS) -1- [1- (acenaphthen-l-yl)piperidin-4-yl] -1, 3-dihydro-2H- benzimidazol-2-one, (R) -1- [1- (acenaphthen-l-yl)ρiperidin-4-yl] -1, 3-dihydro-2H- benzimidazol-2-one,
(S) -1- [1- (acenaphthen-l-yl)piperidin-4-yl] -1, 3-dihydro-2H- benzimidazol-2-one,
(R) -3-acetyl-l- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3- dihydro-2H-benzimidazol-2-one,
(R) -2- { 3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2, 3-dihydro-2- oxo-benzimidazol-l-yl}-N-methylacetamide, and (R) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2-oxo-2- piperazin-1-ylethyl) -1, 3-dihydro-2H-benzimidazol-2-one.
In the present specification, (R) -2-{ 3- [1- (acenaphthen- 1-yl) piperidin-4-yl] -2, 3-dihydro-2-oxo-benzimidazol-l-yl}-N- methylacetamide is the most preferable compound.
The compound represented by the formula (I) can be synthesized according to the methods described in WO03/082333.
In the present specification, (R) -2-{3- [1- (acenaphthen-1- yl) piperidin-4-yl] -2, 3-dihydro-2-oxo-benzimidazol-l-yl}-N- methylacetamide is sometimes to be also referred to as
Compound A. As the pharmaceutically acceptable salt, acid addition salts with inorganic acid and organic acid can be mentioned.
The pharmaceutical agent of the present invention can be administered orally or non-orally. Dosage form includes tablet,
capsule, granule, powder, injection, oral tablet, lotion, liniment, ointment, suppository and the like. These can be formulated by generally used techniques .
The amount of compound (I) or a pharmaceutically acceptable salt thereof, an active ingredient in these formulations, is 0.1 to 100% by weight, suitably 1 to 50% by weight. In addition, the dose may be suitably determined depending on symptoms, age, dosage form and the like. For the oral formulation, the dose is usually 0.1 to 5000 mg, preferably 1 to 1000 mg per day, and may be administered in a single dose or divided doses.
Examples
While Example and Experimental Examples are shown in the following, these Examples are given for better understanding of the present invention, and do not limit the scope of the present invention.
The pharmacological action of the pharmaceutical agent of the present invention is explained by way of Experimental Examples.
Experimental Example 1: Effect on alcohol withdrawal symptoms in Wistar rats. (Experimental method) Male Wistar rats were used in this study. According to the protocol shown in Figure 1, rats were orally given 12-15 g/kg/body weight of ethanol in 24 hours on day 1 to day 2 and 9-10 g/kg/body weight of ethanol in 12 hours on day 3 to day 5. Compound A was administered p.o. at doses of 0.3 and 1 mg/kg/body weight twice after 2 and 7 hours of last ethanol administration. Four types of alcohol withdrawal symptoms such as vocalization, ventromedial limb retraction, tail rigidity, tail tremors were observed and scored with following 3 rating scales: miId=O, moderate=l, severe=2. (Results)
As shown in Figure 2, 0.3 and 1 mg/kg/body weight of Compound A significantly and dose-dependently decreased scores of ventromedial limb retraction, tail rigidity and tail tremors, which were observed 8 to 24 hours after the last 5 ethanol administration.
Experimental Example 2 : Effect on alcohol intake in msP rats.
(Experimental method)
10 Male genetically selected alcohol-preferring rats known as Marchigian Sardinian alcohol-preferring (msP) rats were used in this study (Addiction Biol. 11, 339-355, 2006) . As shown in Figure 3, the rats were housed in reverse light-dark condition (light off at 8:30, light on at 20:30) and ethanol consumption
15 was measured everyday under free choice between water and 10% ethanol. Compound A at doses of 0.3 and 1 mg/kg/body weight was orally administered twice for 9 days at 1 hour before and 8 hours after onset of dark period. (Results)
20 As shown in Figure 4, 0.3 and 1 mg/kg/body weight of
Compound A significantly and dose-dependently decreased ethanol consumption in msP rats. This effect was long-lasting and significant for 9 days after withdrawal of Compound A.
25 Experimental Example 3: Effect on yohimbine-induced reinstatement of alcohol-seeking behavior in msP rats. (Experimental method)
Male genetically selected alcohol-preferring rats known as msP rats were used in this study (Addiction Biol. 11, 339-
30 355, 2006) . As shown in Figure 5, rats were trained to self- administer 10% (w/v) ethanol in 30-min daily sessions under a fixed-ratio 1 (FR 1) schedule of reinforcement, where each response resulted in delivery of 0.1 ml fluid. After acquisition of a stable baseline of 10% ethanol self-
35 administration, rats were subjected to 30-min extinction
sessions for 15 consecutive days. Extinction sessions were identical to 10% ethanol self-administration sessions, however alcohol was no longer available. Beginning on extinction day 10, rats were divided into three groups with similar baseline levels of responding for 10% ethanol. For six consecutive days, 1 hour before the self-administration session and 8 hours later, each group of rats were orally given vehicle, 0.3 mg/kg of Compound A or 1.0 mg/kg of Compound A. After the extinction sessions, rats were given yohimbine (1,25 mg/kg, i.p.) 35 min before the test sessions. The 30-min reinstatement test was conducted under extinction condition.
Yohimbine was used as stressor for this study, because yohimbine is known to produce stress and anxiety-like states in both humans and non-humans (Bremner et al, 1996; Charney et al 1983; Holmberg et al 1963) . (Results)
As shown in Figure 6, treatment with 1 mg/kg of Compound A significantly attenuated yohimbine stress-induced reinstatement of alcohol-seeking behavior.
Experimental Example 4 : Study on dependence elicitation in msP rats. (Experimental method)
A two-compartment box divided by guillotine door was used. As shown in Figure 7, in the first two days, rats were allowed to explore the box with guillotine door open for 15 min (pre-conditioning) . For the following 6 days, the rats were treated on alternate days with three Compound A-pairing administrations (0.3 and 1.0 mg/kg/body weight, p.o.) and three vehicle-pairing administrations immediately before being placed, for 1 hour, into the assigned chamber with guillotine door close for drug-compartment discrimination (conditioning) . The day after the last conditioning session, the rats were placed, for 15 min, in the box with door open. The time spent in the drug paired compartment was measured.
(Results)
As shown in Figure 8, Compound A induced place preference at neither 0.3 nor 1 mg/kg/body weight, suggesting Compound A itself does not elicit dependence. Comparison of pharmacological profiles between Compound A and existing medicines for alcohol dependence is summarized in Table 1. Although naltrexone and acamprosate (both have been marketed in Europe and USA) are effective in excessive alcohol intake, these medicines are ineffective in alcohol withdrawal symptoms and stress-induced reinstatement. Benzodiazepines represented by diazepam are used for a treatment of alcohol withdrawal symptoms, but it is known that benzodiazepines themselves have demerit to induce dependence. Alpha-2 adrenergic agonists represented by clonidine are also effective in alcohol withdrawal symptoms (Dobrydnjov et al., Anesth Analg. 98, 738-744, 2004), but ineffective in excessive alcohol intake and stress-induced reinstatement.
On the other hand, Compound A has not only suppressive effect on excessive alcohol intake, but also ameliorative effect on alcohol withdrawal symptoms and suppressive effect on stress-induced reinstatement. Furthermore, Compound A itself does not elicit dependence. From these results, Compound A is expected to be a good agent for the prophylaxis ■or treatment of alcohol abuse and dependence and other substance abuse and dependence.
Table 1
Example 1: formulation example (tablet)
5 The following ingredients were mixed according to a conventional method in a conventional apparatus and tableted. Compound A 10 mg microcrystalline cellulose 180 mg cornstarch 300 mg io lactose 600 mg magnesium stearate 15 mg
Industrial Applicability
The pharmaceutical agent of the present invention can be is used as an agent for the prophylaxis or treatment of substance abuse and dependence.
This application is based on EP patent application No. 06122336.8 filed on October 16, 2006, the contents of which 20 ' are incorporated in full herein by this reference.
Claims
1. An agent for the prophylaxis or treatment of substance abuse and dependence, which comprises a compound represented by the formula (I)
R1 is
(D hydrogen (2) lower alkyl,
(3) lower alkenyl,
(4) -C(O) -lower alkyl,
(5) -C(0)0-lower alkyl,
(6) -C(O) -phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) ,
(7) lower alkyl-carboxyl,
(8) lower alkyl-C (0) -phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) ,
(9) lower alkyl-C (0) 0-lower alkyl,
(10) lower alkenyl-C (0) 0-lower alkyl,
(11) lower alkyl-O-lower alkyl,
(12) lower alkyl-C (O)NR3R4,
(13) -S(0)2-lower alkyl,
(14) -S (0) 2-phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) ,
(15) lower alkyl-S-lower alkyl,
(16) lower alkyl-S (0) -lower alkyl,
(17) lower alkyl-S (0) 2-lower alkyl,
(18) lower alkyl-S (O)2NR3R4,
(19) phenyl (the phenyl group may be substituted with
lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , or
(20) benzyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , R2 is hydrogen, lower alkyl, halogen, lower alkoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, amino or cyano, R3 and R4 may be the same or different, and each is hydrogen, lower alkyl or lower alkenyl, or R3 and R4 may bind with an adjacent nitrogen atom to form a saturated nitrogen- containing hetero ring (the hetero ring may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , and X is O or S. ) , or a pharmaceutically acceptable salt thereof as an active ingredient.
2. The agent of claim 1, wherein the substance abuse and dependence is abuse of and dependence on alcohol, amphetamine, methamphetamine, cannabis, cocaine, hallucinogens, nicotine, opioids, phencyclidine, ketamine, barbiturates, benzodiazepines or inhalants.
3. The agent of claim 1, wherein the substance abuse and dependence is abuse of and dependence on alcohol.
4. The agent of claim 1, wherein the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof is a compound selected from
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-2H- benzimidazol-2-one,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-5- fluoro-2H-benzimidazol-2-one,
(RS) -1-[1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-β- fluoro-2H-benzimidazol-2-one, ethyl (RS) -2-{ 3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2,3-
dihydro-2-oxo-benzimidazol-l-yl}acetate,
(RS) -2- {3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2, 3-dihydro-2- oxo-benzimidazol-1-yl }acetic acid,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2-oxo-2- piperazin-1-ylethyl) -1, 3-dihydro-2H-benzimidazol-2-one dihydrochloride,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- [2- (4- methylpiperazin-1-yl) -2-oxoethyl] -1, 3-dihydro-2H-benzimidazol- 2-one dihydrochloride, (RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2-morpholin-4- yl-2-oxoethyl) -1, 3-dihydro-2H-benzimidazol-2-one hydrochloride,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-2H- benzimidazole-2-thione,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-3~ methyl-2H-benzimidazole-2-thione,
(R) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-2H- benzimidazol-2-one,
(S) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-2H- benzimidazol-2-one, (R) -3-acetyl-l- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3- dihydro-2H-benzimidazol-2-one,
(R) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3-methanesulfonyl- 1, 3-dihydro-2H-benzimidazol-2-one, ethyl (R) -2- {3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2,3- dihydro-2-oxo-benzimidazol-l-yl}acetate,
(R) -2- { 3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2 , 3-dihydro-2- oxo-benzimidazol-1-yl }acetic acid,
(R) -1-[1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2-oxo-2- piperazin-1-ylethyl) -1, 3-dihydro-2H-benzimidazol-2-one dihydrochloride,
(R) ~2-{ 3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2, 3-dihydro-2- oxo-benzimidazol-l-yl}-N-methylacetamide,
(R) -2- {3- [1- (acenaphthen-1-yl) piperidin-4-yl], -2, 3-dihydro-2- oxo-benzimidazol-1-yl } -N, N-dimethylacetamide, and (R) -2~{3-[l- (acenaphthen-1-yl) piperidin-4-yl] -2, 3-dihydro-2-
oxo-benzimidazol-1-yl } acetamide .
5 . The agent of claim 1, wherein the compound represented by the formula ( I) is (R) -2- { 3- [ 1- (acenaphthen-l-yl) piperidin-4- yl] -2 , 3-dihydro-2-oxo--benzimidazol-l-yl } -N-methylacetamide .
6. Use of a compound represented by the formula (I )
(1) hydrogen,
(2) lower alkyl,
(3) lower alkenyl, (4) -C(O) -lower alkyl,
(5) -C(0)0-lower alkyl,
(6) -C (0) -phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) ,
(7) lower alkyl-carboxyl, (8) lower alkyl-C (0) -phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) ,
(9) lower alkyl-C (0) 0-lower alkyl,
(10) lower alkenyl-C (O) 0-lower alkyl, (11) lower alkyl-O-lower alkyl,
(12) lower alkyl-C (0) NR3R4,
(13) -S(0)2-lower alkyl,
(14) -S (O)2-phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , (15) lower alkyl-S-lower alkyl,
(16) lower alkyl-S (O) -lower alkyl,
(17) lower alkyl-S (O) 2-lower alkyl,
(18) lower alkyl-S (O) 2NR3R4,
(19) phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , or (20) benzyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , R2 is hydrogen, lower alkyl, halogen, lower alkoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, amino or cyano, R3 and R4 may be the same or different, and each is hydrogen, lower alkyl or lower alkenyl, or R3 and R4 may bind with an adjacent nitrogen atom to form a saturated nitrogen- containing hetero ring (the hetero ring may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , and X is 0 or S. ), or a pharmaceutically acceptable salt thereof for the production of an agent for the prophylaxis or treatment of substance abuse and dependence.
1. The use of claim 6, wherein the substance abuse and dependence is abuse of and dependence on alcohol, amphetamine, methamphetamine, cannabis, cocaine, hallucinogens, nicotine, opioids, phencyclidine, ketamine, barbiturates, benzodiazepines or inhalants.
8. The use of claim 6, wherein the substance abuse and dependence is abuse of and dependence on alcohol.
9. The use of claim 6, wherein the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof is a compound selected from
(RS)-I-[I- (acenaphthen-l-yl)piperidin-4-yl]-l,3-dihydro-2H- benzimidazol-2-one, (RS) -l-[l-(acenaphthen-l-yl)piperidin-4-yl]-l,3-dihydro-5-
fluoro-2H-benzimidazol-2-one,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-β- fluoro-2H-benzimidazol-2-one, ethyl (RS) -2-{3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2,3- dihydro-2-oxo-benzimidazol-l-yl } acetate,
(RS) -2-{ 3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2, 3-dihydro-2- oxo-benzimidazol-1-yl } acetic acid,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2-oxo-2- piperazin-1-ylethyl) -1, 3-dihydro-2H-benzimidazol-2-one dihydrochloride,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- [2- (4- methylpiperazin-1-yl) -2-oxoethyl] -1, 3-dihydro-2H-benzimidazol- 2-one dihydrochloride,
(RS) -1-[1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2-morpholin-4- yl-2-oxoethyl) -1, 3-dihydro-2H-benzimidazol-2-one hydrochloride,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-2H- benzimidazole-2-thione,
(RS) -1-[1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-3- methyl-2H-benzimidazole-2-thione, (R) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-2H- benzimidazol-2-one,
(S) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-2H- benzimidazol-2-one,
(R) -3-acetyl-l- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3- dihydro-2H-benzimidazol-2-one,
(R) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3-raethanesulfonyl- 1, 3-dihydro-2H-benzimidazol-2-one, ethyl (R) -2-{3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2, 3- dihydro-2-oxo-benzimidazol-l-yl } acetate, (R) -2-{3-[l- (acenaphthen-1-yl) piperidin-4-yl] -2, 3-dihydro-2- oxo-benzimidazol-1-yl } acetic acid,
(R) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2-oxo-2- piperazin-1-ylethyl) -1, 3-dihydro-2H-benzimidazol-2-one dihydrochloride, (R) -2-{3-[l- (acenaphthen-1-yl) piperidin-4-yl] -2, 3-dihydro-2-
oxo-benzimidazol-1-yl } -N-methylacetamide,
(R) -2- {3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2, 3-dihydro-2- oxo-benzimidazol-l-yl}-N,N-dimethylacetamide, and
(R) -2- {3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2, 3-dihydro-2- oxo-benzimidazol-1-yl }acetamide .
10. The use of claim 6, wherein the compound represented by the formula (I) is (R) -2-{3- [1- (acenaphthen-1-yl) piperidin-4- yl] -2 , 3-dihydro-2-oxo-benzimidazol-l-yl } -N-methylacetamide .
11. A method for the prophylaxis or treatment of substance abuse and dependence, which comprises administering an effective amount of compound represented by the formula (I)
(1) hydrogen,
(2) lower alkyl,
(3) lower alkenyl, (4) -C(O) -lower alkyl,
(5) -C(0)0-lower alkyl,
(6) -C(O) -phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) ,
(7) lower alkyl-carboxyl, [B) lower alkyl-C (0) -phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) ,
(9) lower alkyl-C (0) 0-lower alkyl,
(10) lower alkenyl-C (O) 0-lower alkyl, (11) lower alkyl-0-lower alkyl,
(12) lower alkyl-C (O)NR3R4,
( 13 ) -S (0) 2-lower alkyl,
(14) -S (O)2~phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) ,
(15) lower alkyl-S-lower alkyl, ( 16) lower alkyl-S (O) -lower alkyl,
( 17 ) lower alkyl-S (0) 2-lower alkyl,
( 18 ) lower alkyl-S (0) 2NR3R4,
(19) phenyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , or (20) benzyl (the phenyl group may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , R2 is hydrogen, lower alkyl, halogen, lower alkoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, amino or cyano, R3 and R4 may be the same or different, and each is hydrogen, lower alkyl or lower alkenyl, or R3 and R4 may bind with an adjacent nitrogen atom to form a saturated nitrogen- containing hetero ring (the hetero ring may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy) , and X is O or S. ), or a pharmaceutically acceptable salt thereof.
12. The method of claim 11, wherein the substance abuse and dependence is abuse of and dependence on alcohol, amphetamine, methamphetamine, cannabis, cocaine, hallucinogens, nicotine, opioids, phencyclidine, ketamine, barbiturates, benzodiazepines or inhalants.
13. The method of claim 11, wherein the substance abuse and dependence is abuse of and dependence on alcohol.
14. The method of claim 11, wherein the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof is a compound selected from (RS) -1- [1- (acenaphthen-1-
yl) piperidin-4-yl] -1, 3-dihydro-2H-benzimidazol~2-one,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-5- fluoro-2H-benzimidazol-2-one,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-6- fluoro-2H~benzimidazol-2-one, ethyl (RS) ~2-{ 3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2, 3- dihydro-2-oxo-benzimidazol-1-yl}acetate,
(RS) -2-{3-[l- (acenaphthen-1-yl) piperidin-4-yl] -2, 3-dihydro-2- oxo-benzimidazol-1-yl }acetic acid, (RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2-oxo-2- piperazin-1-ylethyl) -1, 3-dihydro-2H-benzimidazol-2-one dihydrochloride,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- [2- (4- methylpiperazin-1-yl) -2-oxoethyl] -1, 3-dihydro-2H-benzimidazol- 2-one dihydrochloride,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2-morpholin-4- yl-2-oxoethyl) -1, 3-dihydro-2H-benzimidazol-2-one hydrochloride,
(RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-2H- benzimidazole-2-thione, (RS) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-3- methyl-2H-benzimidazole-2-thione,
(R) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-2H- benzimidazol-2-one,
(S) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3-dihydro-2H- benzimidazol-2-one,
(R) -3-acetyl-l- [1- (acenaphthen-1-yl) piperidin-4-yl] -1, 3- dihydro-2H-benzimidazol-2-one,
(R) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3-rαethanesulfonyl- 1, 3-dihydro-2H-benzimidazol-2-one, ethyl (R) -2-{3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2, 3- dihydro-2-oxo-benzimidazol-l-yl } acetate,
(R) -2- {3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2, 3-dihydro-2- oxo-benzimidazol-1-yl}acetic acid,
(R) -1- [1- (acenaphthen-1-yl) piperidin-4-yl] -3- (2-oxo-2- piperazin-1-ylethyl) -1, 3-dihydro-2H-benzimidazol-2-one
dihydrochloride,
(R) -2- {3- [1- (acenaphthen-l-yl)piperidin-4-yl] -2, 3-dihydro-2- oxo-benzimidazol-1-yl } -N-methylacetamide,
(R) -2- {3- [1- (acenaphthen-l-yl)piperidin-4-yl] -2, 3-dihydro-2- oxo-benzimidazol-l-yl}-N,N-dimethylacetamide, and
(R) -2- { 3- [1- (acenaphthen-1-yl) piperidin-4-yl] -2 , 3-dihydro-2- oxo-benzimidazol-1-yl } acetamide .
15. The method of claim 11, wherein the compound represented by the formula (I) is (R) -2-{3- [1- (acenaphthen-1-yl) piperidin- 4-yl] -2, 3~dihydro-2-oxo-benzimidazol-l-yl }-N-methylacetamide .
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2009004012A MX2009004012A (en) | 2006-10-16 | 2007-10-16 | Agent for prophylaxis or treatment of substance abuse and dependence. |
| PL07830236T PL2089030T3 (en) | 2006-10-16 | 2007-10-16 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
| AT07830236T ATE524180T1 (en) | 2006-10-16 | 2007-10-16 | AGENTS FOR THE PROPHYLAXIS OR TREATMENT OF ALCOHOL DEPENDENCE OR DRUG ADDICTION |
| BRPI0717161-7A BRPI0717161A2 (en) | 2006-10-16 | 2007-10-16 | Agent for Prophylaxis or Treatment of Substance Abuse and Dependence. |
| US12/311,861 US8207201B2 (en) | 2006-10-16 | 2007-10-16 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
| KR1020097010031A KR101187509B1 (en) | 2006-10-16 | 2007-10-16 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
| DK07830236.1T DK2089030T3 (en) | 2006-10-16 | 2007-10-16 | Drug for prophylaxis or treatment of alcohol dependence or drug dependence |
| AU2007310209A AU2007310209B2 (en) | 2006-10-16 | 2007-10-16 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
| CA2666630A CA2666630C (en) | 2006-10-16 | 2007-10-16 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
| CN2007800386397A CN101600433B (en) | 2006-10-16 | 2007-10-16 | Agent for prophylaxis or treatment of substance abuse and dependence |
| JP2009515664A JP5089687B2 (en) | 2006-10-16 | 2007-10-16 | Preventive or therapeutic agent for alcoholism or drug dependence |
| EP07830236A EP2089030B1 (en) | 2006-10-16 | 2007-10-16 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06122336 | 2006-10-16 | ||
| EP06122336.8 | 2006-10-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008050698A2 true WO2008050698A2 (en) | 2008-05-02 |
| WO2008050698A3 WO2008050698A3 (en) | 2008-10-02 |
Family
ID=37806857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2007/070502 WO2008050698A2 (en) | 2006-10-16 | 2007-10-16 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8207201B2 (en) |
| EP (1) | EP2089030B1 (en) |
| JP (1) | JP5089687B2 (en) |
| KR (1) | KR101187509B1 (en) |
| CN (1) | CN101600433B (en) |
| AT (1) | ATE524180T1 (en) |
| AU (1) | AU2007310209B2 (en) |
| BR (1) | BRPI0717161A2 (en) |
| CA (1) | CA2666630C (en) |
| DK (1) | DK2089030T3 (en) |
| ES (1) | ES2370276T3 (en) |
| MX (1) | MX2009004012A (en) |
| PL (1) | PL2089030T3 (en) |
| PT (1) | PT2089030E (en) |
| RU (1) | RU2419433C2 (en) |
| WO (1) | WO2008050698A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2345649A1 (en) * | 2008-09-16 | 2011-07-20 | Mitsubishi Tanabe Pharma Corporation | Benzimidazole compound in crystal form and salt thereof |
| CN115611856A (en) * | 2021-07-14 | 2023-01-17 | 宜昌人福药业有限责任公司 | Piperidine derivative and pharmaceutical composition, preparation method and application thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI582096B (en) * | 2011-12-06 | 2017-05-11 | 美國禮來大藥廠 | 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] compounds for the treatment of alcohol dependence and abuse |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036421A1 (en) | 1998-01-19 | 1999-07-22 | Pfizer Pharmaceuticals Inc. | 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists |
| WO2003082333A1 (en) | 2002-03-29 | 2003-10-09 | Mitsubishi Pharma Corporation | Remedy for sleep disturbance |
| WO2005028466A1 (en) | 2003-09-25 | 2005-03-31 | Solvay Pharmaceuticals B.V. | Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006025267A1 (en) * | 2004-08-31 | 2006-03-09 | Mitsubishi Pharma Corporation | Remedy for sleep disorders using lowering in per2 protein level as the action mechanism |
| TW201016675A (en) * | 2008-09-16 | 2010-05-01 | Mitsubishi Tanabe Pharma Corp | Crystalline benzoimidazole compound and salt thereof |
-
2007
- 2007-10-16 CA CA2666630A patent/CA2666630C/en not_active Expired - Fee Related
- 2007-10-16 PT PT07830236T patent/PT2089030E/en unknown
- 2007-10-16 KR KR1020097010031A patent/KR101187509B1/en not_active IP Right Cessation
- 2007-10-16 CN CN2007800386397A patent/CN101600433B/en not_active Expired - Fee Related
- 2007-10-16 BR BRPI0717161-7A patent/BRPI0717161A2/en not_active IP Right Cessation
- 2007-10-16 US US12/311,861 patent/US8207201B2/en not_active Expired - Fee Related
- 2007-10-16 AU AU2007310209A patent/AU2007310209B2/en not_active Ceased
- 2007-10-16 RU RU2009118439/15A patent/RU2419433C2/en not_active IP Right Cessation
- 2007-10-16 DK DK07830236.1T patent/DK2089030T3/en active
- 2007-10-16 JP JP2009515664A patent/JP5089687B2/en not_active Expired - Fee Related
- 2007-10-16 PL PL07830236T patent/PL2089030T3/en unknown
- 2007-10-16 WO PCT/JP2007/070502 patent/WO2008050698A2/en active Application Filing
- 2007-10-16 AT AT07830236T patent/ATE524180T1/en active
- 2007-10-16 EP EP07830236A patent/EP2089030B1/en not_active Not-in-force
- 2007-10-16 MX MX2009004012A patent/MX2009004012A/en active IP Right Grant
- 2007-10-16 ES ES07830236T patent/ES2370276T3/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036421A1 (en) | 1998-01-19 | 1999-07-22 | Pfizer Pharmaceuticals Inc. | 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists |
| WO2003082333A1 (en) | 2002-03-29 | 2003-10-09 | Mitsubishi Pharma Corporation | Remedy for sleep disturbance |
| WO2005028466A1 (en) | 2003-09-25 | 2005-03-31 | Solvay Pharmaceuticals B.V. | Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors |
Non-Patent Citations (19)
| Title |
|---|
| BR. J. PHARMACOL., vol. 129, 2000, pages 1261 - 1283 |
| CICCOCIOPPO ET AL., BIOL PSYCHIATRY, vol. 61, 2007, pages 4 - 12 |
| CICCOCIOPPO ET AL., PSYCHOPHARMACOLOGY (BERL), vol. 172, 2004, pages 170 - 178 |
| CICCOCIOPPO ET AL., PSYCHOPHARMACOLOGY (BERL)., vol. 141, 1999, pages 220 - 224 |
| ECONOMIDOU ET AL., PEPTIDES, vol. 27, 2006, pages 3299 - 3306 |
| EUR. J. PHARMACOL., vol. 340, 1997, pages 1 - 15 |
| FEBS LETT., vol. 341, 1994, pages 33 - 38 |
| FEBS LETT., vol. 347, 1994, pages 284 - 288 |
| KAKKO ET AL., LANCET, vol. 361, 2003, pages 662 - 668 |
| LING ET AL., ADDICTION, vol. 93, 1998, pages 475 - 486 |
| MARTIN-FARDON ET AL., NEUROREPORT., vol. 11, 2000, pages 1939 - 1943 |
| MONTOYA ET AL., CLIN PHARMACOL THER, vol. 75, 2004, pages 34 - 48 |
| NATURE, vol. 377, 1995, pages 532 - 535 |
| PHARMACOL. REV., vol. 53, 2001, pages 381 - 415 |
| SAKOORI ET AL., PSYCHOPHARMACOLOGY (BERL), vol. 172, 2004, pages 129 - 136 |
| SCHOTTENFELD ET AL., BIOL PSYCHIATRY, vol. 34, 1993, pages 66 - 74 |
| SCIENCE, vol. 270, 1995, pages 792 - 794 |
| TESHIMA KOJI ET AL.: "Nonphotic entrainment of the circadian body temperature rhythm by the selective ORL1 receptor agonist W-212393 in rats", BRITISH JOURNAL OF PHARMACOLOGY, vol. 146, no. 1, September 2005 (2005-09-01), pages 33 - 40 |
| ZHAO ET AL., NEUROREPORT., vol. 14, 2003, pages 2383 - 2385 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2345649A1 (en) * | 2008-09-16 | 2011-07-20 | Mitsubishi Tanabe Pharma Corporation | Benzimidazole compound in crystal form and salt thereof |
| EP2345649A4 (en) * | 2008-09-16 | 2012-07-04 | Mitsubishi Tanabe Pharma Corp | Benzimidazole compound in crystal form and salt thereof |
| US8471032B2 (en) | 2008-09-16 | 2013-06-25 | Mitsubishi Tanabe Pharma Corporation | Benzimidazole compound in crystal form and salt thereof |
| CN115611856A (en) * | 2021-07-14 | 2023-01-17 | 宜昌人福药业有限责任公司 | Piperidine derivative and pharmaceutical composition, preparation method and application thereof |
| WO2023284834A1 (en) * | 2021-07-14 | 2023-01-19 | 宜昌人福药业有限责任公司 | Piperidine derivative, and pharmaceutical composition thereof, preparation method therefor, and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US8207201B2 (en) | 2012-06-26 |
| AU2007310209B2 (en) | 2011-11-17 |
| JP5089687B2 (en) | 2012-12-05 |
| PL2089030T3 (en) | 2012-02-29 |
| DK2089030T3 (en) | 2011-12-05 |
| CA2666630A1 (en) | 2008-05-02 |
| CN101600433B (en) | 2012-09-26 |
| US20100069382A1 (en) | 2010-03-18 |
| ES2370276T3 (en) | 2011-12-14 |
| RU2009118439A (en) | 2010-11-27 |
| WO2008050698A3 (en) | 2008-10-02 |
| RU2419433C2 (en) | 2011-05-27 |
| EP2089030B1 (en) | 2011-09-14 |
| KR20090069336A (en) | 2009-06-30 |
| AU2007310209A1 (en) | 2008-05-02 |
| CN101600433A (en) | 2009-12-09 |
| KR101187509B1 (en) | 2012-10-02 |
| EP2089030A2 (en) | 2009-08-19 |
| CA2666630C (en) | 2012-01-24 |
| ATE524180T1 (en) | 2011-09-15 |
| MX2009004012A (en) | 2009-04-27 |
| PT2089030E (en) | 2011-09-27 |
| JP2010505746A (en) | 2010-02-25 |
| BRPI0717161A2 (en) | 2013-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Carroll et al. | Pharmacological properties of JDTic: a novel κ-opioid receptor antagonist | |
| US6310072B1 (en) | Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist | |
| US9226918B2 (en) | Methods and compositions for treating or preventing narcotic withdrawal symptoms | |
| WO2007005716A2 (en) | Methods of treatment and compositions for use thereof | |
| CA2250187A1 (en) | Composition comprising olanzapine and a drug useful in the treatment of pain for use in the treatment of pain | |
| US20070299098A1 (en) | Therapeutic Agent for Neuropathic Pain | |
| KR101630467B1 (en) | Inhibitor of analgesic tolerance | |
| US8207201B2 (en) | Agent for prophylaxis or treatment of alcohol dependence or drug dependence | |
| EP0514023B1 (en) | Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal | |
| Rudd et al. | Modulation of emesis by fentanyl and opioid receptor antagonists in Suncus murinus (house musk shrew) | |
| US20190117637A1 (en) | Pharmaceutical compositions and methods for treatment of pain | |
| WO2009007110A2 (en) | Combination of benzyl-4,5-dihydro-1h-imidazole derivative and an opiod recptor ligand | |
| AU2010295464B2 (en) | Use of opioid receptor antagonist for gastrointestinal tract disorders | |
| KR101492029B1 (en) | Remedy or preventive for integration dysfunction syndrome | |
| CZ174598A3 (en) | Method of treating pain | |
| CA2238815A1 (en) | Composition for treating pain | |
| US20060025434A1 (en) | Therapeutic agents for drug/substance dependence | |
| JPWO2008102859A1 (en) | Drugs for the prevention and / or treatment of anxiety disorders | |
| MXPA00002211A (en) | Noribogaine in the treatment of pain and drug addiction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200780038639.7 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07830236 Country of ref document: EP Kind code of ref document: A2 |
|
| ENP | Entry into the national phase |
Ref document number: 2009515664 Country of ref document: JP Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2666630 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12009500702 Country of ref document: PH |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/004012 Country of ref document: MX |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007310209 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2600/CHENP/2009 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007830236 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020097010031 Country of ref document: KR |
|
| ENP | Entry into the national phase |
Ref document number: 2009118439 Country of ref document: RU Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2007310209 Country of ref document: AU Date of ref document: 20071016 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12311861 Country of ref document: US |
|
| ENP | Entry into the national phase |
Ref document number: PI0717161 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090415 |